Clinical trial · Interventional
Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer
NCT02509871CI-TRIAL-00036186MetaCa2completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This cross-sectional study of pathophysiology will bring additional informations on body composition of patients treated by adjuvant hormonal therapy for breast cancer. This is a complementary study of Metaca study (AU882).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hormonal Therapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Body composition measurement | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Body composition measurement
- description
- DXA, impedance
- interventionNames
- Other: Body composition measurement
Primary outcomes (1)
- measure
- Measure of body composition
- timeFrame
- After more than a year of hormonal therapy
- description
- To obtain additional data to those of Metaca study (AU882) to assess changes in body composition (fat mass, lean body mass in Kg) in women with breast cancer and treated with adjuvant hormonal therapy following chemotherapy
Secondary outcomes (5)
- measure
- Evaluation of the distribution of abdominal fat by measuring the waist and hip circumference
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * postmenopausal women * patients requiring hormonal treatment * WHO performance status 0-2 * patients initially included in MetaCa (AU882) protocol * Affiliation to a social security scheme (or be the beneficiary of such a plan) * patients who signed the informed consent form Exclusion Criteria: * patients witg relapse, with metastases or other cancer * concurrent treatment with a drug test, or participation in a clinical trial within \< 30 days * patients carrying an electronic medical device (eg pacemaker) * patients who refused to sign the consent form
References
Publications (1)
- RESULTGinzac A, Thivat E, Mouret-Reynier MA, Dubray-Longeras P, Van Praagh I, Passildas J, Abrial C, Kwiatkowski F, Boirie Y, Duclos M, Morio B, Gadea E, Durando X. Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments. Clin Breast Cancer. 2018 Oct;18(5):e1093-e1102. doi: 10.1016/j.clbc.2018.06.010. Epub 2018 Jun 18. PMID 30417829